Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL623280 | 1.00 | DPP4 (0.53) | DPP4GRM2SLC1A2SLC1A1EPHX1 | |
| SCHEMBL1053865 | 1.00 | DPP4 (0.53) | DPP4GRM2SLC1A2SLC1A1EPHX1 | |
| SCHEMBL21969684 | 0.97 | DPP4 (0.57) | DPP4GRM2SLC1A2SLC1A1EPHX1 | |
| SCHEMBL16640290 | 0.97 | DPP4 (0.57) | DPP4GRM2SLC1A2SLC1A1EPHX1 | |
| SCHEMBL7868412 | 0.97 | DPP4 (0.57) | DPP4GRM2SLC1A2SLC1A1EPHX1 | |
| SCHEMBL24316913 | 0.97 | DPP4 (0.57) | DPP4GRM2SLC1A2SLC1A1EPHX1 | |
| SCHEMBL21977981 | 0.97 | DPP4 (0.57) | DPP4GRM2SLC1A2SLC1A1EPHX1 | |
| SCHEMBL21981265 | 0.97 | DPP4 (0.57) | DPP4GRM2SLC1A2SLC1A1EPHX1 | |
| SCHEMBL20819999 | 0.97 | DPP4 (0.57) | DPP4GRM2SLC1A2SLC1A1EPHX1 | |
| Cyclohexylglycyl SCHEMBL122348 | 0.97 | DPP4 (0.57) | DPP4GRM2SLC1A2SLC1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267590-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ONCOARENDI THERAPEUTICS S.A. (PL) | 2023-11-01 | — | — | EP | claimed |
| US-20220204530-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2022-06-30 | — | — | US | claimed |
| WO-2022137156-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | Oncoarendi Therapeutics S.A. (PL) | 2022-06-30 | — | — | WO | claimed |
| CN-1109780-A | Sustained-release preparation of anti-endothelin substance | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-10-11 | — | — | CN | claimed |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2026-04-28 | — | — | US | disclosed |
| US-20250115551-A1 | SYNTHESIS OF RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-04-10 | — | — | US | disclosed |
| WO-2025076071-A2 | SYNTHESIS OF RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-12173018-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024163962-A1 | 3-((1,1-DIOXIDO-2,3,4,5-TETRAHYDROBENZO[F][1,2,5]THIADIAZEPIN-8-YL)OXY)-2-FLUOROACRYLIC ACID DERIVATIVES AS SODIUM TAUROCHOLATE CO-TRANSPORTING POLYPEPTIDE (NTCP) INHIBITORS FOR THE TREATMENT OF CHOLESTASIS | Hemoshear Therapeutics, Inc. (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-4267590-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ONCOARENDI THERAPEUTICS S.A. (PL) | 2023-11-01 | — | — | EP | disclosed |
| US-20230303625-A1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | RA PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303625-A1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | RA PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-7871998-B2 | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| EP-1699759-B1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-10-20 | — | — | EP | disclosed |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20080064676-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| EP-1699759-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005061452-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| CN-1109780-A | Sustained-release preparation of anti-endothelin substance | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-10-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115551-A1 | SYNTHESIS OF RAS INHIBITORS | KRAS, NRAS, HRAS | DPP4 3495/4885GRM2 4755/4885SLC1A2 4452/4885 |
| US-20230303625-A1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | PCSK9, LDLR, PCSK7 | DPP4 201/4885GRM2 4523/4885SLC1A2 4880/4885 |
| US-20220204530-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ARG1, ARG2, PRMT1 | DPP4 299/4885GRM2 1840/4885SLC1A2 1068/4885 |
| US-12173018-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | DPP4 416/4885GRM2 4655/4885SLC1A2 2521/4885 |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | CYP46A1, CYP51A1, DHCR7 | DPP4 71/4885GRM2 4853/4885SLC1A2 4412/4885 |
| US-20080064676-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | CYP46A1, CYP51A1, DHCR7 | DPP4 71/4885GRM2 4853/4885SLC1A2 4412/4885 |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, ARGLU1 | DPP4 370/4885GRM2 469/4885SLC1A2 85/4885 |
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | DPP4 4255/4885GRM2 2868/4885SLC1A2 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.